Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 254

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 254
---
 inhibitor payload into cancer cells. Recent Developments

| • |     | Divestiture of FYARRO. On December 19, 2024, we entered into a Stock Purchase Agreement (the                                                                                                                                                    
 “Divestiture Agreement”) with KAKEN INVESTMENTS INC. (“Kaken”) for the sale to Kaken of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (“Aadi Sub”) and thereby all of Aadi’s assets related                          
 to its FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) program (the “FYARRO Business”), which may be deemed to be a sale of substantially all of                                                          
 Aadi’s assets under Section 271 of the Delaware General Corporation Law, as amended. Per the terms and subject to the conditions of the Divestiture Agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain          
 adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, Kaken will also acquire the rights to the Aadi name and 
 trademark.                                                                                                                                                                                                                                      |

License Agreement. On December 19, 2024, we entered into an Intellectual Property License Agreement (the “License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for exclusive rights to certain patents and know-how pertainingto WuXi Biologics’ pre-clinical antibodydrug conjugate programs leveraging Hangzhou DAC Biotechnology Co., Ltd.’s (“Hangzhou DAC”) linker-payload technology targeting each of Mucin-16 (“MUC16”),Protein Tyrosine Kinase 7 (“PTK7”) and Seizure Related 6 Homolog (“SEZ6”) (each an “ADC Program,” and collectively, the “ADC Programs”). Under the License Agreement, we agreed to pay WuXi Biologics a non-refundable, partialupfront payment of $6 million and an additional non-refundable, upfrontpayment of $38 million within ninety (90) days after the effective date of the License Agreement, which may be extended by either party for an additional thirty (30) days, in each case, for the rights and licenses granted to us by WuXi Biologics. In accordance with the License Agreement, WuXi Biologics